Industry

Approval based on recurrence-free survival and distant metastasis-free survival benefit demonstrated by KEYTRUDA in the Phase 3 KEYNOTE-716 trial KEYTRUDA is the first anti-PD-1 immunotherapy approved in the EU for patients 12 years and older as adjuvant treatment across stage IIB, IIC and III melanoma following complete resection and for the treatment of advanced (unresectable … [Read more…]

FRISCO, Texas–(BUSINESS WIRE)–Magellan Healthcare, the behavioral and specialty healthcare segment of Magellan Health, Inc., today announced resources and programs in support of Black, Indigenous and People of Color (BIPOC) Mental Health Awareness Month in July. One in five Americans has been diagnosed with a mental health or substance use condition.1 While BIPOC experience relatively similar … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Global Oscillating Positive Expiratory Pressure Devices Market Forecast to 2028 – COVID-19 Impact and Global Analysis by Product, Indication, and Distribution Channel” report has been added to ResearchAndMarkets.com’s offering. The oscillating positive expiratory pressure (OPEP) devices market is expected to grow from US$ 125.66 million in 2021 to US$ 179.34 million by 2028; … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Peripheral T-Cell Lymphomas Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players” report has been added to ResearchAndMarkets.com’s offering. The report provides comprehensive information on the therapeutics under development for Peripheral T-Cell Lymphomas (PTCL), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Vulvar Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players” report has been added to ResearchAndMarkets.com’s offering. The report provides comprehensive information on the therapeutics under development for Vulvar Cancer, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Global Spinal Fusion Devices Market Size, Share & Industry Trends Analysis Report By Surgery, By Type, By End User (Hospitals, Specialty Clinics, and Others), By Regional Outlook and Forecast, 2022 – 2028” report has been added to ResearchAndMarkets.com’s offering. The Global Spinal Fusion Devices Market size is expected to reach $9.7 billion by … [Read more…]

VS-01 Reduced Plasma Metabolites Associated with Organ Failures Related to ACLF Metabolomic analysis of organ failure markers abstract selected for inclusion in the ‘Best of International Liver Congress™ 2022’ ZURICH–(BUSINESS WIRE)–Versantis, a clinical-stage biotechnology company developing novel therapies for orphan and pediatric liver diseases, today announced data showing both single and repeated intraperitoneal administrations of … [Read more…]

Largest multinational survey highlights impact of pruritus on quality of life for patients with primary sclerosing cholangitis FOSTER CITY, Calif.–(BUSINESS WIRE)–Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) presented data at the International Liver Congress™ of The European Association for the Study of the Liver (EASL) in London, United Kingdom. The first analysis featured a multinational survey of … [Read more…]

LONDON–(BUSINESS WIRE)–SC1, London’s new Life Sciences Innovation District being developed in south central London, UK, has announced the appointment of a new Executive Director, Georgina Rizik. Georgina is a leading international healthcare and biotechnology commercial executive with over 25 years’ experience across private, public and non-profit organisations. Starting in June, Georgina will lead SC1, which … [Read more…]

MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News: Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, is pleased to announce the participation of CEO Nawal Ouzren in the LifeSci Partners 2nd Annual Genetic Medicines Symposium being held … [Read more…]